Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen Inc. EVP, Operations Arleen Paulino reported 4,455 directly held common shares, including 2,181 restricted stock units and 66 dividend equivalents, plus 2,039.9774 shares represented by interests in the company’s stock fund through the 401(k) Plan. Her report also lists non-qualified stock options, including 5,314 options at a $236.36 exercise price, vested and exercisable, and 7,166 options at $235.97, of which 4,729 are vested. The first tranche expires May 5, 2030; the latter expires May 2, 2033, with its remaining options scheduled to vest and become exercisable on May 2, 2027. Other listed tranches have differing exercise prices and vesting schedules, including installments beginning in 2027.
Amgen Inc. director Omar Ishrak acquired 152 shares of common stock in a grant/award transaction on November 6, 2026. His reported direct holdings following the transaction were 7,682 shares. The notes state that the Restricted Stock Units were immediately vested and are paid in common stock on a one-to-one basis.
Amgen (AMGN) director Charles M. Holley acquired 185 common shares on November 6, 2026, through restricted stock units that vested immediately and are paid in common shares one-to-one. His direct holdings after the award were 13,262 shares; 1,260 shares were held indirectly through the Holley Family Trust. A footnote says the reported shares include 1,739 dividend equivalents.
Amgen director David W. Gibbs acquired 278 common shares on November 6, 2026, through restricted stock units granted under the company's director equity incentive program. The units vested immediately, and Gibbs directly held 278 shares following the transaction. Vested units are paid in common stock on a one-to-one basis; payment may be deferred according to the director's elected schedule.
Amgen Inc. director Michael V. Drake received an award of 114 shares on November 6, 2026. The award consisted of restricted stock units (RSUs) that vested immediately; vested RSUs are paid in common shares on a one-to-one basis, and the director may defer payment under an elected schedule. His reported direct holdings after the transaction were 6,030 shares, including 417 dividend equivalents credited to unvested RSUs.
Amgen Inc. reported third-quarter 2026 revenue of $10.365 billion and net income of $3.864 billion for the three months ended September 30, 2026, compared with $9.557 billion and $3.216 billion a year earlier. Operating income was $3.710 billion versus $2.526 billion, and diluted earnings per share were $7.08 versus $5.93. Product sales were $9.883 billion; Repatha sales were $1.085 billion versus $794 million, while Prolia sales were $632 million versus $1.139 billion.
For the first nine months of 2026, revenue was $29.037 billion and net income was $8.058 billion, compared with $26.885 billion and $6.378 billion in 2025. Operating cash flow was $10.432 billion versus $8.355 billion; cash and cash equivalents were $13.190 billion at September 30, 2026, and debt carrying value was $54.007 billion. Amgen paid $4.083 billion in dividends during the period and declared an October 2026 quarterly dividend of $2.52 per share, payable in December 2026.
Amgen Inc. reported third-quarter 2026 revenue of $10.4 billion, up 8% year over year. GAAP EPS rose 19% to $7.08 from $5.93, and non-GAAP EPS rose 14% to $6.45 from $5.64. GAAP operating margin was 37.5%, up 9.9 percentage points; non-GAAP operating margin was 47.3%, up 0.2 points. Seventeen products delivered at least double-digit sales growth, and 17 products were annualizing at more than $1 billion based on third-quarter sales.
Product sales included Repatha at $1.085 billion, up 37%, while Prolia sales fell 45% to $632 million as multiple biosimilars launched globally. Free cash flow was $3.7 billion versus $4.2 billion a year earlier, driven by working-capital changes; the 2025 period benefited from rebate and collection timing, partially offset by current-period business performance. Operating cash flow was $4.2 billion versus $4.7 billion.
Amgen paid a third-quarter dividend of $2.52 per share, a 6% increase from the same period in 2025. For the year ending December 31, 2026, diluted EPS guidance is $18.34 to $19.28 on a GAAP basis and $22.90 to $23.70 on a non-GAAP basis.
Amgen appointed David W. Gibbs as a director, effective immediately. Following the appointment, the Board will have 13 directors, 12 of whom are independent.
Gibbs will receive standard non-employee director compensation, including a prorated portion of the $115,000 annual cash retainer and $12,500 committee member meeting retainers through December 31, 2026. His annual fully vested restricted stock unit grant has a grant date fair value of $220,000; he will receive a prorated 7/12 portion two business days after the release of Amgen’s 2026 third-quarter earnings.
AMGEN INC (AMGN) reported the initial equity holdings of executive vice president and chief financial officer Thomas J.W. Dittrich on a Form 3. He directly holds 16,860 Restricted Stock Units (RSUs) that will be settled in common stock and non-qualified stock options covering 17,201 shares of common stock at an exercise price of $410.95 per share.
The RSUs and the options were granted under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan and each vest in four equal annual installments of 25% beginning on August 7, 2027. The options are exercisable on this schedule and expire on August 7, 2036.